NEW YORK, Sept. 16, 2025 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced a comprehensive shareholder update, underscoring momentum across its lead clinical programs and corporate strategy. With HT-001 advancing globally, HT-KIT […]
